TCR2 THERAPEUTICS INC.·4

Nov 2, 2:00 PM ET

Hofmeister Robert 4

4 · TCR2 THERAPEUTICS INC. · Filed Nov 2, 2020

Insider Transaction Report

Form 4
Period: 2020-10-29
Hofmeister Robert
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2020-10-29$0.74/sh+20,000$14,80058,850 total
  • Sale

    Common Stock

    2020-10-29$19.10/sh20,000$382,00038,850 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-10-2920,00022,346 total
    Exercise: $0.74From: 2018-12-07Exp: 2027-12-07Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on by the reporting person.
  • [F2]25% of this option vested and become exercisable on December 7, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION